EDUARDO ZINONI SILVA PATO
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
7 resultados
Resultados de Busca
Agora exibindo 1 - 7 de 7
conferenceObject INFLUENCE OF TREATMENT WITH HYPERTONIC SOLUTION BEFORE EVLP ON DONORS WITH HEMORRHAGIC SHOCK(2015) NEPOMUCENO, Natalia; OLIVEIRA-BRAGA, Karina Andrighetti; RUIZ, Liliane Moreira; CORREIA, Aristides Tadeu; SILVA, Eduardo Zinoni; PEGO-FERNANDES, Paulo Manuel; SAMANO, Marcos Naoyuki- Pediatric lung transplantation: 10 years of experience(2014) CAMARGO, Priscila C. L. B.; PATO, Eduardo Z. S.; CAMPOS, Silvia V.; AFONSO JR., Jose E.; CARRARO, Rafael M.; COSTA, Andre N.; TEIXEIRA, Ricardo H. O. B.; SAMANO, Marcos N.; PEGO-FERNANDES, Paulo M.Lung transplantation is a well-established treatment for advanced lung diseases. In children, the diseases that most commonly lead to the need for a transplantation are cystic fibrosis, pulmonary hypertension, and bronchiolitis. However, the number of pediatric lung transplantations being performed is low compared with the number of transplants performed in the adult age group. The objective of this study was to demonstrate our experience with pediatric lung transplants over a 10-year period in a program initially designed for adults.
conferenceObject DEEP DORSAL VEIN BED PLICATION FOR VENTRAL PENILE CURVATURE(2023) ZANDONA, Pedro Caetano Edler; BARROS, Guilherme Garcia; COIMBRA, Igor Valente; GOES, Plinio Moreira De; PATO, Eduardo Zinoni Silva; NAHAS, William Carlos; NASCIMENTO, Bruno Chiesa Gouveia; HALLAK, Jorge- Experience of Lung Transplantation in Patients with Lymphangioleiomyomatosis at a Brazilian Reference Centre(2017) BALDI, Bruno Guedes; SAMANO, Marcos Naoyuki; CAMPOS, Silvia Vidal; OLIVEIRA, Martina Rodrigues de; AFONSO JUNIOR, Jose Eduardo; CARRARO, Rafael Medeiros; TEIXEIRA, Ricardo Henrique Oliveira Braga; MINGUINI, Isabela Pasqualini; BURLINA, Roni; PATO, Eduardo Zinoni Silva; CARVALHO, Carlos Roberto Ribeiro; COSTA, Andre NathanLung transplantation (LT) is the standard of care for patients with advanced lung diseases, including lymphangioleiomyomatosis (LAM). LAM accounts for only 1% of all LTs performed in the international registry. As a result, the global experience, including the use of mechanistic target of rapamycin (mTOR) inhibitors before and after LT in LAM, is still limited. We conducted a retrospective review of all LAM patients who underwent LT at our centre between 2003 and 2016. Pre- and post-transplant data were assessed. Eleven women with LAM underwent LT, representing 3.3% of all procedures. Ten (91%) patients underwent double-LT. The mean age at diagnosis was 39 +/- 6 years and the mean FEV1 before LT was 28 +/- 14%. Only one patient underwent pleurodesis for recurrent pneumothorax. Pulmonary hypertension was confirmed in 3 (27%) patients. Four (36%) patients received sirolimus preoperatively; three of them received it until the day of LT, and there was no occurrence of bronchial anastomotic dehiscence after the procedure. Four patients (36%) received mTOR inhibitors post-transplant. The median follow-up from LT was 44 months. There were 3 deaths (27%) during the study and survival probabilities at 1, 3, and 5 years after LT were, 90, 90, and 77%, respectively. This data reinforces the role of LT for LAM patients with end-stage disease. The use of sirolimus seems to be safe before LT and the occurrence of complications after LT, including those LAM-related, should be continuously monitored.
- Lung transplantation for lymphangioleiomyomatosis: a Brazilian centre experience(2017) OLIVEIRA, Martina; BALDI, Bruno Guedes; SAMANO, Marcos Naoyuki; CAMPOS, Silvia Vidal; TEIXEIRA, Ricardo Henrique Oliveira Braga; MINGUINI, Isabela Pasqualini; BURLINA, Roni; PATO, Eduardo Zinoni Silva; CARVALHO, Carlos Roberto Ribeiro; COSTA, Andre Nathan
- Effect of hypertonic saline in the pretreatment of lung donors with hemorrhagic shock(2018) NEPOMUCENO, Natalia Aparecida; OLIVEIRA-BRAGA, Karina Andrighetti de; RUIZ, Liliane Moreira; CORREIA, Aristides Tadeu; PATO, Eduardo Zinoni Silva; SILVA, Luiz Fernando da; PEGO-FERNANDES, Paulo Manuel; SAMANO, Marcos NaoyukiBackground: Hemorrhagic shockeinduced lung edema and inflammation are two of the main reasons for the rejection of lungs donated for transplantation. Hypertonic saline (HS) induces intravascular volume expansion and has considerable immunomodulating effects that might minimize edema. Our hypothesis is based on the use of a hypertonic solution for treatment of donors who are in shock in an attempt to increase the supply of lungs for transplantation. Methods: A total of 80 rats were allocated to four groups: one group was given an infusion of normal saline (NS; n = 20), one group received HS; n = 20, a sham group (n = 20), and a Shock group (n = 20). Half of the lungs from each group were evaluated in an ex vivo perfusion system, and the other half was used for measurements of cytokine levels and neutrophil counts. Results: In the ex vivo perfusion assessment, the pulmonary artery pressures of the animals in the NS and HS groups did not exhibit significant differences compared with those in the sham group (P > 0.05) but were lower than those in the Shock group (P < 0.01). Furthermore, the tumor necrosis factor-alpha levels and neutrophil counts were lower in the HS group than those in the Shock group (P < 0.01) and did not exhibit significant differences compared with those in either the NS and Sham groups (P > 0.05). Conclusions: We showed that HS was equivalent to isotonic saline and contributed to the treatment of lungs subjected to hemorrhagic shock.
- Clinical and Pathological Predictors of Death for Adrenocortical Carcinoma(2024) PATO, Eduardo; SROUGI, Victor; ZERBINI, Claudia; LEDESMA, Felipe L.; TANNO, Fabio; ALMEIDA, Madson Q.; NAHAS, William; LATRONICO, Ana Claudia; MENDONCA, Berenice B.; CHAMBO, Jose L.; V, Maria Candida B. FragosoAdrenocortical carcinoma (ACC) is a rare and lethal disease with a poor prognosis. This study aims to share our 41-year experience as a referral center, focusing on identifying risk factors associated with ACC mortality. Our retrospective analysis included a cohort of 150 adult patients with ACC in all stage categories, treated between 1981 and 2022. Tumor hormonal hypersecretion was observed in 78.6% of the patients, and the median age of diagnosis was 40 years. The majority presented as European Network for the Study of Adrenal Tumors (ENSAT) III or IV (22.9% and 31.2%, respectively), and the overall mortality rate was 54.6%. Independent predictors of death were elevated secretion of cortisol (HR = 2.0), androstenedione (HR = 2.2), estradiol (HR = 2.8), 17-OH progesterone (HR = 2.0), and 11-deoxycortisol (HR = 5.1), higher Weiss (HR = 4.3), modified Weiss (HR = 4.4), and Helsinki scores (HR = 12.0), advanced ENSAT stage (HR = 27.1), larger tumor size (HR = 2.7), higher Ki-67 percentage (HR = 2.3), and incomplete surgical resection (HR = 2.5). Mitosis greater than 5/50 high-power field (HR = 5.6), atypical mitosis (HR = 2.3), confluent necrosis (HR = 15.4), venous invasion (HR = 2.8), and capsular invasion (HR = 2.4) were also identified as independent predictors of death. Knowing the risk factors for ACC's mortality may help determine the best treatment option.